Regencell Bioscience Holdings Limited
RGC
Rank in Stocks
#3383
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in... Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.
Share Price
$10.41
Last synced: 2026-10-20
Market Cap
$5.16B
Change (1 day)
3.56%
Change (1 year)
-35.07%
Country
HK
Trade Regencell Bioscience Holdings Limited (RGC)
Category
Healthcare
Revenue for Regencell Bioscience Holdings Limited (RGC)
Revenue in Jun 2026 TTM: 0.00
According to Regencell Bioscience Holdings Limited latest financial reports the company's current revenue (TTM) is 0.00. In 2024 the company made a revenue of 0.00 equal to the revenue in the year 2023 that was 0.00. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Regencell Bioscience Holdings Limited from 2019 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2025 | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | - |
IN
|
